Use of Maraviroc (MVC) in Immunological Non-Responder HIV-1-Infected Patients.

Trial Profile

Use of Maraviroc (MVC) in Immunological Non-Responder HIV-1-Infected Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 15 Oct 2011 Results presented at the 13th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top